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Chronic hepatitis C virus (HCV) infection can lead to liver cirrhosis in up to 20% of individuals, often requiring liver transplan-
tation. Although the new liver is known to be rapidly reinfected, the dynamics and source of the reinfecting virus(es) are unclear,
resulting in some confusion concerning the relationship between clinical outcome and viral characteristics. To clarify the dy-
namics of liver reinfection, longitudinal serum viral samples from 10 transplant patients were studied. Part of the E1/E2 region
was sequenced, and advanced phylogenetic analysis methods were used in a multiparameter analysis to determine the history
and ancestry of reinfecting lineages. Our results demonstrated the complexity of HCV evolutionary dynamics after liver trans-
plantation, in which a large diverse population of viruses is transmitted and maintained for months to years. As many as 30 inde-
pendent lineages in a single patient were found to reinfect the new liver. Several later posttransplant lineages were more closely
related to older pretransplant viruses than to viruses detected immediately after transplantation. Although our data are consis-
tent with a number of interpretations, the persistence of high viral genetic variation over long periods of time requires an active
mechanism. We discuss possible scenarios, including frequency-dependent selection or variation in selective pressure among
viral subpopulations, i.e., the population structure. The latter hypothesis, if correct, could have relevance to the success of newer
direct-acting antiviral therapies.
The hepatitis C virus (HCV; family Flaviviridae, genus Hepaci-virus) infects more than 180 million people worldwide and is a
leading global cause of liver disease and cancer (3, 26). Since indi-
viduals can remain asymptomatic for decades, the true prevalence
is potentially much greater than current estimates of 3% of the
world population (50). At present, no vaccine is available, and
pharmacological treatment is only moderately successful, partic-
ularly for the most prevalent subtypes circulating in the United
States and Europe (3), due in part to a prolonged asymptomatic
phase of chronic infection that hinders early identification of HCV
transmission among individuals. Although the use of direct-act-
ing antiviral drugs (including two recently licensed protease in-
hibitors) offer improved sustained antiviral response rates (29),
drug treatments will not be successful in all patients (47), and
antiviral resistance is likely to play a significant role in treatment
failure (21). Thus, chronic HCV infection remains a major public
health concern.
Liver cirrhosis develops in up to 20% of HCV-infected individ-
uals, who will eventually require a liver transplant (3). However,
the new liver is infected within minutes following transplant (16),
serum viral load increases 10- to 20-fold relative to pretransplant
levels (12), and the clinical course of disease is accelerated (11).
Characteristics of the infecting virus and its anatomical source(s)
are unknown, reflecting the lack of a practical and realistic small
animal model (30) and challenges in culturing the virus in vitro.
The evolutionary rate of HCV within an infected host is on the
order of 103 nucleotide substitutions/site/year (1, 17), resulting
in rapid accumulation of mutations over time and circulation of
variable viral populations. High variability permits detailed inves-
tigation of HCV evolutionary dynamics during infection. The
structural E1 and E2 genes evolve fastest (13) and have the stron-
gest phylogenetic signal (40) as a result of encoding proteins that
are recognized by the host immune system. Several studies report
that some or most of the pretransplant diversity in the E1E2 region
is lost during a viral bottleneck that follows transplantation, pos-
sibly reflecting the outgrowth of fitter variants (2, 8, 9, 16, 32, 41,
42). In contrast, some evidence suggests that posttransplant viral
dynamics are more complex than a simple population bottleneck;
for example, the dominant variant at 7 days posttransplant does
not persist in later samples in all cases (2, 42), and the minor
variant pretransplant can become dominant (14). An observed
bottleneck could be explained by a founder effect of colonization
of the new liver, or result from methodological limitations such as
consensus sequencing (28) or single-strand conformation poly-
morphisms (2, 32) and the use of summary statistics (9, 32, 37,
41), which fail to elucidate evolutionary relationships or structure
(39, 44); grouping results from multiple patients rendering data
interpretation difficult (9, 27, 32, 41, 42); and temporally restric-
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tive sampling schemes that limit investigation of long-term evo-
lutionary trends (8, 9, 16, 37).
We investigated here the long-term evolution of HCV pre- and
posttransplant in 10 patients to determine the effect of the trans-
plant on viral dynamics. A longitudinal sampling strategy, span-
ning at least 1 to 2 years pre- and posttransplant, was combined
with high-resolution phylogenetic methods to define the evolu-
tionary relationships in the virus population pre- and posttrans-
plantation. We found that the patterns of reinfection were more
complex than previously reported; when appropriate population
genetic methods are used, no evidence of a significant viral genetic
bottleneck appears following transplantation, and transmitted
minor variants can persist for long periods of time. The dynamics
of posttransplant reinfection may reflect the poorly understood
process of transmission to new hosts with novel immune back-
grounds and selective pressures.
MATERIALS AND METHODS
Amplification and sequencing. Serum samples were collected before and
after liver transplantation at the University of North Carolina Liver Cen-
ter under an Institutional Review Board-approved protocol with written
informed consent from all participants. Patient characteristics are de-
scribed in Table 1. Viral RNA was extracted using the QIAamp viral RNA
minikit (Qiagen, Valencia, CA). The cDNA synthesis and amplification
was performed in a single step, using the Superscript One Step RT-PCR
system with Platinum Taq DNA polymerase (Life Technologies, Grand
Island, NY) according to the manufacturer’s conditions with the excep-
tion of the primer concentration and thermocycling conditions. For the
reaction mix 0.8 M concentrations of the primers E1_F_3_1_HCV (5=-
ATGGCNTGGGAYATGATRATGAA-3=) and E2_R_1_1_HCV (5=-TTC
ATCCABGTRCARCCRAACCA-3=) were used with 60 ng of RNA tem-
plate/l. Also, 0.8 M concentrations of the primers E1_F_3_1_HCV
(5=-ATGGCNTGGGAYATGATRATGAA-3=) and E2_R_2_1_HCV (5=-
CCYCGNGTCCARTTGCA-3=) were used for the samples that failed ini-
tial amplification. The primer designs and extracted RNA were provided
by the Wang laboratory at the University of Florida. The first set spans a
716-bp region, and the second 995-bp region of the env region of HCV
subtype 1, which includes the hypervariable regions. The thermocycling
conditions consisted of 50°C for 30 min and 94°C for 2 min, followed by
35 cycles of 94°C for 1 min, 48°C for 1 min, and 72°C for 1 min, with a final
step of 72°C for 10 min. A plasmid containing the full-length sequence of
H77C and nontemplate samples were used as controls. The amplicons
were run on a 1.5% agarose gel in buffer Tris-acetate-EDTA for confir-
mation of amplification. Each reaction was performed one time point at a
time to prevent cross-contamination. Amplified samples were cloned by
using a TOPO TA cloning kit (Life Technologies) according to the man-
ufacturer’s conditions. Both directions of the individual clones were se-
quenced at the University of Florida’s Interdisciplinary Center for Bio-
technology Research facility using the TOP10-specific M13 forward
primer and the M13 reverse primer. All sequences were assembled using
CodonCode software (CodonCode Corp., Dedham, MA). The analyzed
sequences spanned from nucleotides 1316 to 1984 relative to the reference
H77 genome (accession number NC_004102).
Nucleotide diversity. Serum HCV sequences were obtained for three
to five time points surrounding surgery, ranging from 1 to 12 months and
2 years pretransplant, and within 4 months, 6 to 14 months, and 20
months posttransplant. For each patient and time point, an average of 24
cloned sequences was obtained (range, 19 to 33 sequences). The sequences
were separately aligned manually using BioEdit for each patient. The nu-
cleotide diversity at each time point (mean pairwise genetic distances) was
calculated separately using a maximum-likelihood correction and gam-
ma-distributed rate variation among sites. Standard errors were calcu-
lated using 200 bootstrapped replicates. These analyses were performed in
MEGA v.4 (46).
Bayesian rate and coalescent growth models. Bayesian phylogenetic
analyses were performed using the HKYG model of nucleotide substi-
tution, with independent estimates at the codon 12 and 3 positions,
implemented in the program BEAST v.1.6 (4). Convergence was assessed
by visual examination of traces and ensuring all effective sampling size
(ESS) values of 200 in the program Tracer v.1.5. Initially, a constant size
coalescent prior with the strict molecular clock was assumed. This was
then compared to a model that used a relaxed molecular clock that allows
uncorrelated rate variation among lineages. Both of these models assumed
constant population diversity through time.
The constant diversity assumption was relaxed and a “two-epoch”
model was used (7), with the date of the transplant used as a strong prior
for the transition time between epochs. All parameters were held constant
across the two epochs except for the population size parameters. Two
different epoch models were tested: one in which the population diversity
was constant in each of the epochs and one in which the population
diversity increased exponentially.
Finally, the Bayesian skyline plot model was used; this model allows
the population diversity to change throughout time (5, 35). The marginal
likelihoods of competing models were compared using Bayes factors.
Strong evidence in favor of the alternative model is provided when 2(lnL
model 1  lnL model 2) is 10 (45).
Estimation of new lineages. In order to estimate the number of lin-
eages that emerged posttransplant, we counted the number of changes
between two phylogenetic states (pre- and posttransplant). Sequences











A 51 Male C G0S1-2 –32.4 (21), 4.4 (22), 2.3 (24), 12.4 (23) 64,000/700,000 NA/335
B 57 Male C G3S2 –19.0 (23), 0.8 (24), 1.0 (22), 12.2 (22) 374,000/687,000 143/211
C 51 Male C G2-3S2 –23.8 (26), 7.7 (24), 1.5 (24), 12.6 (24), 20.1 (24) 47,100/691,000 228/81
D 44 Male NAm NA –18.1 (33), 3.8 (23), 1.6 (19), 12.7 (23), 27.0 (23) NA/2,510,000 79/40
F 48 Male AA G2S0 –24.4 (23), 4.7 (24), 1.5 (24), 14.6 (26), 34.1 (24) 342,000/700,000 82/139
G 53 Male C G2S1 –20.1 (24), 2.3 (23), 6.5 (22) 369,000/1,710,000 146/149
H 54 Male AA G2S0 –9.5 (20), 1.1 (19), 3.3 (27), 38.8 (25) 293,000/5,000,000 76/31
I 48 Male C G1S0 –28.1 (23), 2.2 (36), 1.9 (28), 24.9 (26) 426,000/700,000 85/54
J 53 Male C G2S0 –57.1 (25), 10.4 (26), 1.5 (24), 7.6 (25) 584,000/NA 60/36
L 65 Male C G2-3S1 –23.4 (24), 1.1 (21), 1.6 (23), 13.2 (24), 23.2 (24) 108,000/4,890,000 65/272
a TP, transplantation; NA, not available.
b The numbers of clones at each time point are indicated in parentheses.
c C, Caucasian; AA, African American; NAm, Native American.
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were coded as one of the two states, and internal nodes states were recon-
structed using parsimony with an irreversible matrix, such that only
pre- to posttransplant state changes were permitted (as implemented
in MacClade). For each patient, the mean and 95% confidence inter-
vals (95% CI) of the number of emergent lineages were calculated from
the distribution of changes across the posterior distribution of trees
(minus a 10% burn-in).
Maximum-likelihood trees. Maximum-likelihood phylogenies were
inferred in PhyML (15) using a general time reversible (GTR) model of
nucleotide evolution and gamma-distributed rate variation among sites,
with no molecular clock enforced. Each patient was analyzed separately.
with all time points included. A total of 200 bootstrap replicates were
performed to assess the statistical support for the topologies. Trees were
visualized and annotated in FigTree v.1.3 and rooted according to the
“best root” option in Pathogen v.1.2 (http://tree.bio.ed.ac.uk/software
/pathogen).
Selection analysis. Alignments from each of the 10 patients were
tested using the single-likelihood ancestor counting (SLAC) and fixed-
effects likelihood (FEL) methods to detect site-specific selection via an
online server (http://www.datamonkey.org [33]). These methods were
chosen for their applicability to large (50 taxa) data sets and short se-
quences. The best-fitting model of nucleotide substitution was used. An
alpha value of 0.05 was used to assess significance.
Nucleotide sequence accession numbers. Nucleotide sequences for
the HCV strains have been deposited in GenBank under accession num-
bers JQ063473 to JQ064506.
RESULTS
Clinical cohort. Ten patients included in the study were male and
between the ages of 44 and 57 (Table 1). In all but one case (patient
B) the patients were alive at the time of the study. Serum samples
were obtained for three to five time points surrounding surgery,
ranging from 1 to 12 months and 12 months pretransplant and
4 months, 6 to 14 months, and 20 months posttransplant. A
liver biopsy performed after the transplant indicated variable pro-
gression to fibrosis with all patients showing mild to moderate
progression (G  3).
Nucleotide diversity. First, to evaluate the expectation of a
sharp decrease in diversity posttransplant under the bottleneck
model, sample diversities were calculated as the mean pairwise
genetic distance among sampled sequences for each patient/time
point without taking into account phylogenetic relationships
among sequences (Fig. 1). Sample diversities across patients were
variable, ranging from 0.01 substitutions/site (patient G) to 
0.07 substitutions/site (patient A). No consistent trend in decreas-
ing genetic diversity during the initial 4 months posttransplant
was apparent. In patient F, diversity significantly increased in the
first sample posttransplant relative to the diversity present 5
months pretransplant. No significant change in sample diversity
at the first time point posttransplant was found in six patients,
while a significant decrease was detected in three patients (A, D,
and I).
Over longer periods of time (6 to 15 months posttransplant),
viral diversity showed no trend across patients. A statistically sig-
nificant increase in diversity appeared in patients A and D relative
to the first sample posttransplant, while a statistically significant
decrease was observed for patients J, B, and F. In the six patients
with a sample  20 months posttransplant (D, I, C, F, H, and L),
two (D and H) exhibited a statistically significant increase in ge-
netic diversity relative to the previous samples. In patient F, sam-
ple diversity 34 months posttransplant was similar to diversity in
the sample 1 month posttransplant, even though a transient re-
duction in diversity appeared in the sample taken 14 months post-
transplant. In two patients (C and L) a significant decrease in
diversity was observed by 20 and 23 months posttransplant, re-
spectively, compared to the previous time point.
Overall, evidence for a bottleneck model using the common
approach of mean pairwise diversity was identified in only three of
the 10 subjects (A, D, and I), while in seven subjects stable or
increased posttransplant diversity supported an alternative expla-
nation.
Coalescent growth models. Several evolutionary models that
incorporate phylogenetic relationships among sequences were
considered to quantify changes in the diversity of the whole viral
population over time. First, a strict molecular clock model (all
lineages evolve at the same rate) was compared against a more
general relaxed clock model (which allows lineages to evolve at
different rates). By comparing the marginal likelihoods of the two
models using Bayes factors (BFs), the relaxed clock model was
strongly favored over the simpler strict clock for all 10 patients (BF
 50), providing a rational for using the relaxed clock model in all
subsequent analyses.
Next, population genetic diversity through time for each pa-
tient was estimated using a Bayesian skyline plot (BSP) model,
which includes estimates of statistical uncertainty (5). Under a
bottleneck scenario, a sharp reduction in the relative population
FIG 1 Sample genetic diversity in serum. Plots are shown for patients A to L.
Sample genetic viral diversity was assessed for all samples in 10 HCV patients
using maximum-likelihood corrected pairwise nucleotide distances for all se-
quences at a given time point. For each patient, the y axis shows estimated
genetic diversity. The x axis represents time going forward. Each of the light
gray vertical bars  1 year. The gray shaded area represents the time after the
transplant. Mean and standard error are denoted with a circle and bars.
Gray et al.
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genetic diversity around the time of transplantation would be ex-
pected if a limited number of founder viruses successfully estab-
lish infection in the new liver, whether resulting from stochastic or
deterministic forces. BSPs showed no significant reduction in
population genetic diversity at the time of the transplant across
patients (Fig. 2). Most patients showed constant population diver-
sity throughout infection, suggesting that the transplant did little
to disrupt the overall diversity of the population. Although five
patients (A, D, I, J, and B) showed a slight decline in HCV popu-
lation diversity around the time of the transplant, the decrease was
well within the wide confidence intervals and thus not significant.
We then compared the fit of the general BSP model to a much
simpler model of constant population diversity; only for patient B
was the BSP strongly favored (BF  10) over the simpler model.
Interestingly, patient B was not one of the patients in the previous
analysis identified as displaying a putative bottleneck. Thus, in
9/10 cases a model of constant population diversity cannot be
rejected.
We next tested two-epoch models. First, viral populations were
allowed to have one level of genetic diversity before transplant and
another level afterwards (white and gray areas, respectively, in Fig.
2). Alternatively, the posttransplant diversity was allowed to in-
crease exponentially. Neither epoch model was favored over the
simplest model of constant diversity through time (BF  10). The
results are consistent with those from the BSPs and overall suggest
that the viral population diversity remained unchanged after the
transplant.
Phylogenetic analysis. To understand the evolutionary history
of the posttransplant virus, maximum clade credibility genealo-
gies assuming a relaxed molecular clock and constant population
diversity were inferred. The expectation under a bottleneck sce-
nario was that only one lineage, representing the founder virus
that survived the bottleneck and initiated infection in the new
liver, would emerge after transplantation and that all subsequent
posttransplant viruses would share a common ancestor with this
founder strain.
The bottleneck signature was observed for patient G, in which
the vast majority of sequences sampled within 4 months post-
transplant clustered together (Fig. 3). In contrast, multiple origins
of the posttransplant viral population were observed for 9 of 10
patients. Unexpectedly, viruses sampled within 4 months post-
transplant often shared a common ancestor with viruses from 2 or
more years pretransplant, rather than the time point immediately
pretransplant. For example, in patients B and F, a major lineage
containing sequences from 1 to 2 months posttransplant, respec-
tively, shared an ancestor with viruses sampled at 19 and 24
months posttransplant, creating a distinct clade that includes no
sequences sampled 1 and 5 months posttransplant (bottom clade
in both patients in Fig. 3).
In several cases (e.g., patients J, B, and G), sequences sampled
within 4 months posttransplant gave rise to the majority of lin-
eages present in the sample 6 to 15 months posttransplant. Unex-
pectedly, in other cases some lineages sampled 6 to 15 months
posttransplant did not share a origin with the 0- to 4-month post-
transplant sample but rather with an earlier sample (e.g., patients
A, D, C, and L). In some of these cases, the origin of the 6- to
15-month posttransplant sample was quite close to the root (e.g.,
patients A and D), indicating that the lineage was in existence—
but not detected—for a period of years.
Of the six patients with a sample 20 months posttransplant
(D, I, C, F, H, and L), four (D, I, F, and H) showed multiple
lineages containing sequences from this last time point. Interest-
ingly, again, some of these clades did not share an ancestor with
the immediately preceding time point, but rather one further back
in time. In patient D, most of the sequences from 27 months
posttransplant shared an ancestor with the pretransplant viruses
pretransplant, in a clade that contained no sequences from 1 or 12
months posttransplant. In patient H, the major clades containing
the 38 month posttransplant sequences did not contain any se-
quences from 3 months posttransplant but rather exclusively pre-
transplant sequences. The other two patients (C and L) had a
single clade containing sequences sampled 20 months post-
transplant. We used a phylogenetic method to estimate the num-
ber of viral lineages that survive the transplantation process (Table
2). The mean number of surviving lineages summed over all trees
in the posterior distribution (the same as used to generate the
MCC tree, above) ranged from 1 (patient G) to 15 (patients A and
D). In only one instance did the distribution of the estimated
number of re-emerging lineages include 1 (patient G), providing
strong evidence for multiple posttransplant founder lineages.
Maximum-likelihood trees showed a similar pattern (data not
shown).
FIG 2 Population genetic diversity. Plots are shown for patients A to L. For
each patient, the y axis shows estimated genetic diversity. The x axis represents
time going forward. Each of the vertical bars  1 year. The gray shaded area
represents the time after the transplant. The black curve gives the mean esti-
mate of the BSP, and the red area indicates the 95% high posterior density
intervals.
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Overall, these results demonstrate that a wide section of pre-
transplant diversity is maintained through the posttransplant in-
fection. In some cases, the dominant major variant at a later post-
transplant time point appears to have evolved from a lineage
present at a level below detection (5%) for many months or even
years. Only patient G showed the expected pattern of a bottleneck
scenario in the phylogenetic tree; however, note that this patient is
unique in only having three time points represented. These results
contrast with the apparent signal of a bottleneck for patients A, D,
and I in the sample diversity analysis, which demonstrates the
importance in incorporating phylogenetic relationships when
testing such hypotheses (39).
Selection analysis. For each patient, we used two methods—
TABLE 2 Number of distinct posttransplant lineages
Patient












a 95% CI, 95% confidence interval.
FIG 3 Bayesian phylogenies. Trees are shown for patients A to L where branches are scaled in time with vertical lines indicating years (drawn relative to the last
sample). Terminal branches are colored according to the time of sampling: black  pretransplant, red  1 to 3 months posttransplant, blue  3 to 20 months
posttransplant, green  20 months posttransplant. Internal branches are colored according to the maximum-parsimony reconstruction of the time of
sampling with a time-forward enforcement. Asterisks indicate posterior support  0.9, and thick branches indicate a lineage containing a positively selected site.
Gray et al.
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SLAC and FEL—for detecting site-specific positive selection (Ta-
ble 3). In 7 of 10 patients, at least one site was detected as signifi-
cantly under positive selection (P  0.05). In general, FEL
identified additional sites over SLAC, which is consistent with the
conservative nature of the SLAC test (20). In one case (patient D),
FEL failed to detect a site that was identified by SLAC. In total, 22
different sites across the seven patients were detected as being
under positive selection. The majority (12/22) were in the hyper-
variable region (HVRI) region of E2 (amino acids 384 to 410 rel-
ative to H77 reference genome), which contains epitopes for neu-
tralizing antibodies and may also act as an epitope for helper (43)
and cytotoxic (48) T cells. The two sites identified for patient B
were localized in epitopes for monoclonal antibodies that contain
contact residues for CD81 cellular receptor binding (18, 19).
Changes at these sites were then mapped onto the specific lin-
eages on the MCC trees (Fig. 3). In general, positive selection was
present throughout the history of the infection, indicating ongo-
ing adaptive evolution. In several cases (patients D, I, F, and L),
these sites were found on posttransplant lineages that led to one of
the majority variants.
DISCUSSION
Our study revealed that multiple HCV lineages are transmitted at
the time of liver transplant without a major decrease in viral ge-
netic diversity. Although only some of the pretransplant lineages
are identified within the first 4 months posttransplant, lineages are
undoubtedly present because their ancestors are sampled at later
time points. The data clearly argue against a bottleneck scenario in
most transplant recipients and suggest that little restriction of di-
versity occurs in the new liver in which multiple lineages set up a
new infection.
It could be suggested that a restriction in the viral population is
unlikely to be observed in the 4 months posttransplant, since in-
sufficient time has elapsed and patients are typically on immuno-
suppressive drugs during this period that may reduce the selective
pressure on the virus. However, we show the absence of a trans-
plantation bottleneck for as long as 1 to 2 years posttransplant.
Although analysis of sample genetic diversity was consistent with a
bottleneck in 3/10 patients (A, D, and I), subsequent population
genetic analyses plainly demonstrated by multiple parameters that
the genetic bottleneck signature failed to apply to the virus popu-
lations in these patients and that estimates based on sample diver-
sities have underestimated the actual diversity of the viral popula-
tion.
Furthermore, multiple distinct viral lineages sampled a year or
more after transplant share a ancestor with viruses sampled well
before (2 years) transplant, rather than with viruses sampled
within 4 months posttransplant, as would be expected for a con-
tinuously replicating virus. Our sequencing strategy allowed for
detection of viral variants at 5% level (average of 24 clones/time
point). Thus, it is possible—and indeed very likely—that variants
belonging to these unobserved lineages were present in the serum
at levels below our threshold of detection. However, a fundamen-
tal tenet arising from molecular evolutionary theory is that, in the
absence of a active mechanism of maintenance, segregating vari-
ants in a population will be lost, either due to fixation (via random
genetic drift or positive selection) or due to elimination (via ge-
netic drift or negative selection). The mean survival time of very
rare segregating variants (whether advantageous, neutral, or del-
eterious) is particularly short as a result of their high probability of
stochastic extinction (see, for example, reference 38). Thus, the
persistence of rare variants over long periods of time requires an
active evolutionary force, such as frequency-dependent selection
(whereby the fitness of a variant declines as its frequency in-
creases) or spatially conditioned selective pressure that results in
local adaptations (and thus population structure) (31). Our pres-
ent study cannot distinguish between these two possibilities. In
the latter, the population structure could arise from spatial segre-
gation in the liver or from virus replication in additional anatomic
compartments (39). For example, hepatic lymph nodes (37) and
peripheral blood mononuclear cells (25) have been suggested pos-
sible extra-hepatic sources of infection for the new liver. Other
possible reservoirs include macrophages (23, 24, 36), the central
nervous system (10, 22), and/or B cells (6). However, previous
models have suggested that only a small fraction of posttransplant
viruses originate from these sources (34).
Primer/PCR bias is unlikely to be a factor in the detection of the
major variants, as a bias would differentially affect the pool of
variants such that one particular type would be preferentially am-
plified. In the present data set, however, entirely different variants
were amplified at various time points. PCR misincorporation er-
rors and/or recombination would not account for the deep lineage
structure observed. Interestingly, an ongoing independent analy-
sis of the clinical samples studied here using pyrosequencing of the
NS3 region with a limit of detection of 1% suggests a similar
pattern in which clades contain sequences from well before and
after transplant, but none from the time points surrounding the




Site dN/dS P Site dN/dS P
A 330 7.35 0.04 330 3.90 0.05
405 9.92 0.01 399 4.79 0.03




B 397 16.06 0.02 397 35.06 0.01
477 14.55 0.02
C None None
D 533 6.31 0.02 532 6.06 0.02





I None 445 7.81 0.04
J 445 4.99 0.04 386 2.32 0.05




L None 384 3.31 0.03
394 3.42 0.05
401 2.23 0.03
a Numbering is indicated relative to the H77 reference genome. Boldfacing indicates a
position within HVRI (amino acids 382 to 410); italics indicate a position in a defined
epitope (amino acids 425 to 443 and 529 to 535).
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operation (G. Wang, unpublished data). This observation will be
investigated further in future work.
A complex suite of selective pressure is likely to operate on the
virus in this cohort, including the potentially strong selective pres-
sure of a new liver expressing different HLA alleles, as well as a
potential reduction in host immune pressure as a result of immu-
nosuppressive therapy. Positively selected sites were detected in 7
of 10 patients, mainly in the HVRI region. These sites are most
likely to be under diversifying selection as methods using the
dN/dS test within a population are the most sensitive to this type of
selection, and this region is known to be the target of T and B cell
immune responses. Lineages containing sites under positive selec-
tion were distributed through time and in several cases led to one
of the dominant variants posttransplant, indicating a potential
selective advantage of those variants.
The results of the present study differ significantly from those
reported previously. Our study included a longer temporal sam-
pling strategy and used more extensive analysis methods. Al-
though mean pairwise genetic distance measures of sample diver-
sity are one method for assessing bottlenecks, the statistic is readily
confounded when the sampled population is structured into sub-
populations (49) because pairwise distance ignores the phyloge-
netic relationships among samples. In contrast, measures of pop-
ulation diversity explicitly take in account the phylogenetic
relationships among samples and can infer the presence of un-
sampled lineages at earlier time points from the observation of
their descendants at later times. In addition, a long-term sampling
strategy that included viruses sampled from several years before
and after the transplant revealed the nature and complexity of the
viral population that reinfects the new liver, which would have
been obscured by a simple cross-sectional analysis immediately
after the transplant.
All virus populations in the present study were obtained from
serum. Although such viruses are often assumed to represent the
viral population in the liver, serum viruses may also contain vari-
ants from nonhepatic sites. Future studies should include both
liver biopsies and long-term temporal sampling to understand the
dynamics of transplant reinfection.
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